Abstract:Antidepressant drugs such as the serotonin (5-HT)/norepinephrine (NE) and dopamine (DA) reuptake inhibitors activate monoaminergic neurotransmission in various brain regions, such as the amygdala, the frontal cortex or the hippocampus. Although this property is well established, the post-synaptic mechanisms by which these pharmacological agents exert therapeutic activity in major depressive disorders (MDD) is not fully understood. Recent clinical and preclinical studies have indicated that the density and reactivity of glia and more particularly of astrocytes are reduced in MDD patients. These data along with the fact that astrocytes express monoaminergic transporters and receptors make these cells putative targets for antidepressant treatments. Accordingly, in vitro evidence has demonstrated that the application of various classes of antidepressant drugs on rodent primary astrocyte cultures elicits a wide spectrum of responses, from the rise in cytosolic calcium concentrations, as a marker of cellular activity, to the release of glucose metabolites, gliotransmitters and neurotrophic factors. Remarkably, antidepressant drugs also attenuate the release of inflammatory molecules from reactive astrocytes or microglia, suggesting that part of the beneficial effects in depressed patients or animal models of depression might result from the ability of antidepressants to regulate the synthesis and release of psychoactive substances acting on both pre- and post-synaptic neurons. Among the many long-term targets of antidepressant drugs, brainderived neurotrophic factor (BDNF) has been well studied because of the positive influence on adult hippocampal neurogenesis, synaptogenesis and the local serotonergic tone. This review will illustrate how the concept of the tripartite synapse, which is classically associated with different forms of plasticity involving glutamate, could be expanded to the monoaminergic systems to regulate antidepressant drug responses. The recent in vivo data supporting that hippocampal astrocytes act in concert with neurons to release BDNF under pharmacological conditions and thereby regulate different facets of anxiolytic-/antidepressant-like activities through neurogenesis-dependent and independent mechanisms will be emphasized.

[Killer activities of peripheral blood mononuclear cells in patients with bladder cancer].

Molecular basis of human noradrenaline transporter reuptake and inhibition

Transport and inhibition mechanisms of the human noradrenaline transporter

Uncovering the Elusive Structures and Mechanisms of Prevalent Antidepressants

Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters.

Involvement of Organic Cation Transporter 2 Inhibition in Potential Mechanisms of Antidepressant Action

Interaction of antidepressants with the serotonin and norepinephrine transporters: mutational studies of the S1 substrate binding pocket

Monoamine transporters: vulnerable and vital doorkeepers.

Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines

The antidepressant desipramine is an arrestin-biased ligand at the α(2A)-adrenergic receptor driving receptor down-regulation in vitro and in vivo

[Heterogeneity of anti-protein antibodies].

Amphetamine Derivatives as Potent Central Nervous System Multitarget SERT/NET/H3 Agents: Synthesis and Biological Evaluation

Design, synthesis and biological evaluation of arylpropylamine derivatives as potential multi-target antidepressants

Antidepressant-induced membrane trafficking regulates blood-brain barrier permeability

Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study.

Substrate binding and inhibition mechanism of norepinephrine transporter

The mechanism of a high-affinity allosteric inhibitor of the serotonin transporter

Recent Developments in the Design of Anti-Depressive Therapies: Targeting the Serotonin Transporter

Computational Characterization of the Selective Inhibition of Human Norepinephrine and Serotonin Transporters by an Escitalopram Scaffold

Azepines and piperidines with dual norepinephrine dopamine uptake inhibition and antidepressant activity.

The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs